Caris Life Sciences Analyst Price Targets - Benzinga

Caris Life Sciences Inc

CAINASDAQ

Trade with Public

Trade with Public

$32.96

-1.37-3.99%

마지막 업데이트: Nov 2, 11:37 AM

개요 뉴스 실적 전망 이벤트목표가재무 심리 지분 현황 배당금 비교 주식 보고서

© 2026 Benzinga | All Rights Reserved

Caris Life Sciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Caris Life Sciences (CAI).

Price Target Range — 6 Quarters

Analyst Consensus — 11 Analysts

8Buy

3Hold

Consensus RatingBuy# Analysts11Avg. Consensus PT$31Upside to Avg. PT-7.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 27, 2026	BTIG	Mark Massaro	PT Raise	Buy	$33→$38
Oct 19, 2026	Canaccord Genuity	Kyle Mikson	PT Raise	Hold	$22→$30
Oct 14, 2026	JP Morgan	Casey Woodring	PT Raise	Overweight	$25→$35
Oct 13, 2026	TD Cowen	Dan Brennan	PT Raise	Buy	$30→$36
Sep 9, 2026	UBS	Doug Schenkel	Initiate	Neutral	$28
Aug 6, 2026	BTIG	Mark Massaro	PT Raise	Buy	$32→$33
Aug 6, 2026	Evercore ISI Group	Vijay Kumar	PT Raise	Outperform	$25→$26
Aug 5, 2026	JP Morgan	Casey Woodring	PT Cut	Overweight	$30→$25
Jul 6, 2026	Evercore ISI Group	Vijay Kumar	PT Cut	Outperform	$30→$25
Jul 2, 2026	BTIG	Mark Massaro	Maintained	Buy	$32
Jun 2, 2026	Wolfe Research	Mike Polark	Assumes	Peer Perform	—
May 8, 2026	Citigroup	Patrick Donnelly	PT Cut	Buy	$35→$28
May 8, 2026	JP Morgan	Casey Woodring	PT Cut	Overweight	$35→$30
May 8, 2026	BTIG	Mark Massaro	PT Cut	Buy	$38→$32
Apr 13, 2026	Jefferies	Tycho Peterson	Initiate	Buy	$28
Apr 10, 2026	Piper Sandler	David Westenberg	Initiate	Neutral	$21
Apr 6, 2026	Evercore ISI Group	Vijay Kumar	PT Cut	Outperform	$34→$30
Mar 13, 2026	Canaccord Genuity	Kyle Mikson	PT Cut	Hold	$30→$22
Feb 27, 2026	Evercore ISI Group	Vijay Kumar	PT Cut	Outperform	$38→$34
Feb 27, 2026	Baird	Catherine Schulte	PT Raise	Outperform	$26→$28

Analyst Ratings News

PRO
BTIG Maintains Buy on Caris Life Sciences, Raises Price Target to $38

BTIG analyst Mark Massaro maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and raises the price target from $33 to $38.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Hold on Caris Life Sciences, Raises Price Target to $30

Canaccord Genuity analyst Kyle Mikson maintains Caris Life Sciences (NASDAQ:CAI) with a Hold and raises the price target from $22 to $30.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Caris Life Sciences, Raises Price Target to $36

TD Cowen analyst Dan Brennan maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and raises the price target from $30 to $36.

Benzinga Newsdesk

PRO
Evercore ISI Group Maintains Outperform on Caris Life Sciences, Raises Price Target to $26

Evercore ISI Group analyst Vijay Kumar maintains Caris Life Sciences (NASDAQ:CAI) with a Outperform and raises the price target from $25 to $26.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Caris Life Sciences, Maintains $32 Price Target

BTIG analyst Mark Massaro reiterates Caris Life Sciences (NASDAQ:CAI) with a Buy and maintains $32 price target.

Benzinga Newsdesk

PRO
Wolfe Research Assumes Caris Life Sciences at Peer Perform

Wolfe Research analyst Mike Polark assumes Caris Life Sciences (NASDAQ:CAI) with a Peer Perform rating.

Benzinga Newsdesk